Dulaglutide vs Pal-GHK
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
DulaglutideSkin & CosmeticAnti-Aging & Longevity
Pal-GHK- Summary
- Dulaglutide (brand name Trulicity) is a once-weekly GLP-1 receptor agonist approved by the FDA for type 2 diabetes management and cardiovascular risk reduction. It consists of two GLP-1 analog chains fused to a modified IgG4 Fc fragment, extending its half-life to approximately 5 days. While primarily a diabetes medication, it produces meaningful weight loss and has established cardiovascular outcomes data from the REWIND trial.
- Pal-GHK is the palmitoylated form of the GHK tripeptide without a copper ion. By conjugating palmitic acid to glycine-histidine-lysine, skin penetration is substantially enhanced, enabling deeper dermal collagen stimulation. It is commonly paired with Pal-GHK-Cu or GHK-Cu in anti-aging formulations.
- Half-Life
- ~5 days
- Extended (lipid depot in stratum corneum)
- Admin Route
- SubQ
- Topical
- Research
- —
- —
- Typical Dose
- 0.75 mg → 1.5 mg
- 0.005–0.1% in formulation
- Frequency
- Once weekly
- Once or twice daily
- Key Benefits
- FDA-approved for type 2 diabetes
- Once-weekly subcutaneous dosing via auto-injector pen
- Reduces HbA1c by approximately 1.1–1.6%
- Modest weight loss of 1.5–3 kg at approved doses
- Demonstrated cardiovascular risk reduction (REWIND trial)
- Established long-term safety profile
- Renal protective effects in CKD
- Stimulates collagen I and III synthesis in dermis
- Reduces the appearance of fine lines and wrinkles
- Improves skin elasticity and firmness
- Inhibits collagenase (MMP-1) to preserve existing collagen
- Enhances wound healing and skin repair
- Well-tolerated in anti-aging serums and creams
- Side Effects
- Nausea (most common, typically transient)
- Diarrhea
- Vomiting
- Decreased appetite
- +3 more
- Generally very well-tolerated
- Rare skin irritation at very high concentrations
- Possible formulation-dependent comedogenicity
- Stacks With
- —
- —